1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65262C2B2A1365B64652577EC00241A69
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/gardasil-case-study-springboard-for-successful-market-entry?opendocument
18
19opendocument
2054.163.20.123
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Gardasil Case Study: Using Policy as a Springboard for Launch Success

ID: 5108


Features:

36 Info Graphics

2 Data Graphics

23 Narratives


Pages/Slides: 49


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Gardasil Case Study: Using Policy as a Springboard For Launch Success"

STUDY OVERVIEW

Gardasil is a vaccine manufactured by Merck that prevents certain diseases caused by the Human Papillomavirus (HPV), including cervical cancer and genital warts. Although the vaccine's cost is high, Gardasil achieved blockbuster status by focusing on public (government) and private (managed markets) policymakers as part of key pre- and post-launch activities. This case study reviews how Gardasil's launch followed Merck's new global commercial model, the hurdles the vaccine faced in the public arena, and how Merck used a value argument to overcome pricing and other concerns. The study also highlights Merck's lobbying efforts to make the vaccine mandatory and the consequent backlash that caused the company to ease up on its lobbying efforts related to Gardasil. Other topics addressed in the study are Merck's education efforts directed at different physician groups and parents/young adults, and how the company dealt with controversy.

Using secondary research and an interview with a senior Merck strategy executive, Best Practices, LLC created this case study to assess the winning strategies that led to Gardasil's market success. Executives can use this study to understand Merck's approach to using policy as a springboard for a successful market entry and how it can be used in other launch efforts.

KEY TOPICS

  • Product and disease state profiles
  • Merck’s global commercial model
  • Expedite global approvals & policy recommendations
  • Quick and broad public and private funding
  • Strong uptake among providers
  • Parent and young adult female motivation
  • Dealing with controversy

SAMPLE KEY FINDING
  • Educate policymakers in both public and private sectors about costs of targeted disease state and value of new products: Diabetes and cardiology therapeutic areas are each huge cost drivers for both the public and private healthcare sectors. In launching a high-cost new product that impacted a low-visibility area (HPV), Merck focused early education on the long-term cost of HPV. These messages were disseminated to policymakers who control the purse strings for healthcare spending and formulary access.
  • Use value message for providers and consumers as they can influence payer/policy decisions: Education and marketing activities for providers and patients can play an important role in influencing critical public policy and payer positions on reimbursement. Use the same value arguments as well as quality of life benefits that were used for policymakers/payers - sharpen focus to relate to target groups.

METHODOLOGY

Insights were drawn from secondary research and an extensive interview with one of Merck's senior strategy executives.


Industries Profiled:
Pharmaceutical; Health Care


Companies Profiled:
Merck


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.